|2.75 0.2 (7.84%)||12-01 16:00|
|Targets||6-month :||4.06||1-year :||4.74|
|Resists||First :||3.48||Second :||4.06|
|Supports||First :||2.33||Second :||1.62|
|MAs||MA(5) :||2.55||MA(20) :||2.21|
|MA(100) :||2.19||MA(250) :||2.19|
|MACD||MACD :||0||Signal :||-0.1|
|%K %D||K(14,3) :||94.2||D(3) :||94.1|
|52-week||High :||3.48||Low :||1.3|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IRIX ] has closed Bollinger Bands are 35.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||2.79 - 2.8||2.8 - 2.81|
|Low:||2.49 - 2.51||2.51 - 2.52|
|Close:||2.73 - 2.75||2.75 - 2.77|
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Wed, 01 Nov 2023
Pre -market Movers: CLLS, PAYC, WE, IRIX, GDEV… - Nasdaq
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||16 (M)|
|Shares Float||12 (M)|
|Held by Insiders||25.3 (%)|
|Held by Institutions||23.2 (%)|
|Shares Short||177 (K)|
|Shares Short P.Month||87 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0.74|
|Profit Margin||-14.3 %|
|Operating Margin||-13.2 %|
|Return on Assets (ttm)||-13.1 %|
|Return on Equity (ttm)||-51.5 %|
|Qtrly Rev. Growth||-12.2 %|
|Gross Profit (p.s.)||1.56|
|Sales Per Share||3.36|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-7 (M)|
|Levered Free Cash Flow||-2 (M)|
|Price to Book value||3.71|
|Price to Sales||0.81|
|Price to Cash Flow||-6.07|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|